endometrial
No description yet: the sentence for this tag has not been written. 9 records carry it: 9 people.
Related tags
9 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Amanda Nickles Fader Gynaecologic oncologist, Johns Hopkins · Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer. | p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer | none | gynaecological, trialist | ||
Ana Oaknin Head of the Gynaecological Cancer Programme, Vall d'Hebron Institute of Oncology, Barcelona · Vall d'Hebron University Hospital / VHIO Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers. | Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Cervical cancer | none | gynaecological, immunotherapy, trialist | ||
Carien L. Creutzberg Professor of Radiation Oncology, Leiden University Medical Center · Leiden University Medical Center Led the PORTEC trials that defined who needs radiotherapy for endometrial cancer and brought molecular classification into treatment decisions. | Endometrial cancer | none | radiotherapy, molecular-classification | ||
Douglas A. Levine Director of Gynecologic Oncology, NYU Langone Perlmutter Cancer Center · Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Surgeon-scientist who led the TCGA endometrial cancer study that created today's four molecular subtypes. | Endometrial cancer, Ovarian cancer | none | genomics, surgery | ||
Mansoor Raza Mirza Chief Oncologist, Rigshospitalet, Copenhagen University Hospital; Chair, ENGOT · Rigshospitalet, Copenhagen University Hospital Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer. | Endometrial cancer, Ovarian cancer | none | ovarian, trialist | ||
Ramez N. Eskander Professor of Obstetrics, Gynecology and Reproductive Sciences, UC San Diego Moores Cancer Center · UC San Diego Moores Cancer Center Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease. | Endometrial cancer | none | immunotherapy, nrg-oncology | ||
Remi A. Nout Professor of Radiation Oncology, Erasmus MC, Rotterdam · Erasmus MC Cancer Institute Dutch radiation oncologist who was lead author of PORTEC-2, the trial that showed vaginal brachytherapy is as good as pelvic radiotherapy for high-intermediate-risk endometrial cancer, with fewer side effects. | Endometrial cancer with no specific molecular profile, Endometrial cancer, Cervical cancer | none | radiotherapy, trialist | ||
Shannon N. Westin Gynaecologic oncologist, MD Anderson Cancer Center · MD Anderson Cancer Center Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer. | Advanced or recurrent endometrial cancer, Endometrial cancer, Ovarian cancer | none | gynaecological, trialist | ||
Vicky Makker Gynaecologic medical oncologist, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy. | Advanced or recurrent endometrial cancer, Endometrial cancer | none | gynaecological, immunotherapy, trialist |